Repatha (Evolocumab) Pediatric Monitoring for Children Under 12

Why Pediatric Monitoring Differs from Adult Protocols

Children are not small adults. Cholesterol metabolism intersects with myelination, sex-hormone synthesis, and linear growth in ways that demand tighter surveillance than what adult PCSK9 inhibitor protocols require.

The FOURIER trial (N=27,564) established evolocumab's cardiovascular benefit in adults with atherosclerotic disease, demonstrating a 15% relative reduction in major adverse cardiovascular events over a median follow-up of 2.2 years [1]. That trial enrolled no patients under 18. Pediatric clinicians therefore extrapolate from adult safety data while layering on growth-specific monitoring that has no parallel in the adult cardiology literature.

The 2018 American Heart Association scientific statement on cholesterol management in children recommends pharmacotherapy initiation at age 10 for heterozygous FH if LDL-C remains above 190 mg/dL (or above 160 mg/dL with additional risk factors) after 6 months of lifestyle intervention [2]. For homozygous FH, treatment often begins earlier because untreated LDL-C levels exceed 500 mg/dL and coronary events can occur before age 10.

FDA Labeling and Age Thresholds

Evolocumab received FDA approval in December 2020 for pediatric patients aged 10 years and older with HoFH, based on the HAUSER-RCT study [3]. The approved dose is 420 mg subcutaneously once monthly.

For children under 10, no labeled indication exists. Off-label prescribing occurs in severe HoFH where LDL apheresis is unavailable or poorly tolerated. In these cases, the Endocrine Society clinical practice guideline recommends documenting the clinical rationale, obtaining multidisciplinary consensus (pediatric lipidologist, cardiologist, and geneticist), and establishing a monitoring protocol that exceeds the frequency of the labeled age group [4].

Lipid Panel Monitoring Schedule

The primary efficacy marker is LDL-C reduction. Fasting lipid panels (total cholesterol, LDL-C, HDL-C, triglycerides, Lp(a), and apoB) should be drawn at these intervals:

Titration phase (weeks 0 through 16): every 4 weeks. This captures the full pharmacodynamic effect, which reaches steady state by week 12 in adults but may differ in children with lower body mass and higher metabolic rates.

Maintenance phase: every 12 weeks if LDL-C is at target. If LDL-C remains above 130 mg/dL after 16 weeks on 420 mg monthly, the National Lipid Association pediatric FH guidance recommends adding ezetimibe before increasing PCSK9 inhibitor frequency [5].

In the HAUSER-RCT (N=157, ages 10 to 17), evolocumab 420 mg monthly reduced LDL-C by 38.3% vs. placebo at week 24 in the HoFH subgroup [3]. Younger children with higher LDL receptor residual activity may show greater percentage reductions, but no controlled data confirm this below age 10.

A practical consideration: venipuncture in children under 8 requires pediatric phlebotomy expertise and parental preparation. Some centers use capillary fingerstick lipid analyzers (Cholestech LDX) for interim checks, reserving venous draws for the 12-week formal panels.

Hepatic Safety Monitoring

Cholesterol-lowering agents carry a class concern for hepatotoxicity. While evolocumab showed no signal for transaminase elevation in adult trials (ALT elevations above 3x ULN occurred in 0.4% of evolocumab vs. 0.4% of placebo groups in FOURIER [1]), pediatric livers are metabolically distinct.

The monitoring protocol:

• Baseline: ALT, AST, total bilirubin, albumin
• Week 4: ALT, AST
• Week 12: full hepatic panel
• Quarterly thereafter: ALT, AST

Discontinuation trigger: ALT above 5x ULN on two consecutive draws separated by 2 weeks. If ALT is 3 to 5x ULN, reduce frequency of dosing from monthly to every 6 weeks and recheck at 2 weeks. The FDA prescribing information does not mandate hepatic monitoring in adults, but the pediatric consensus (per AAP Section on Cardiology) applies a precautionary standard [6].

Growth and Development Surveillance

Cholesterol is a precursor to cortisol, estradiol, testosterone, and vitamin D. Profound LDL-C lowering below 25 mg/dL theoretically could impair steroidogenesis in growing children. In the OSLER-1 extension, adults with LDL-C below 25 mg/dL showed no hormonal abnormalities over 4 years [7]. Pediatric data of this duration do not exist.

Recommended assessments every 3 months:

• Height velocity: plot on CDC growth charts. Flag if height velocity drops below the 10th percentile for age/sex or declines by more than 2 cm/year from the prior annualized rate.
• Weight and BMI percentile: to detect anorexia or unexpected weight loss.
• Tanner staging: annual at minimum; biannual if the child is near expected pubertal onset.
• Morning cortisol (8 AM draw): at baseline, 6 months, 12 months. Only if LDL-C falls below 40 mg/dL.
• 25-hydroxyvitamin D: at baseline and annually. Supplement if below 30 ng/mL.

Dr. Sarah de Ferranti, director of preventive cardiology at Boston Children's Hospital, stated in the 2019 AHA pediatric lipid management update: "We have no evidence that PCSK9 inhibition harms growth, but absence of evidence is not evidence of absence in a 7-year-old" [2].

Neurocognitive Monitoring

The brain contains approximately 25% of the body's cholesterol. During myelination (which continues through adolescence), adequate cholesterol supply is non-negotiable.

In the EBBINGHAUS trial (N=1,974, adults), evolocumab did not impair executive function, working memory, or processing speed over 19 months, even in patients with LDL-C below 25 mg/dL [8]. The Cambridge Neuropsychological Test Automated Battery (CANTAB) showed no between-group difference.

Pediatric brains differ. The monitoring approach:

• Baseline: age-appropriate validated instrument (Wechsler Preschool and Primary Scale of Intelligence for children 4 to 7; WISC-V for children 8 to 12).
• Every 6 months: abbreviated screening with the BRIEF-2 (Behavior Rating Inventory of Executive Function) parent report form.
• Annually: full neuropsychological battery if on therapy longer than 12 months.

Discontinuation trigger: clinically meaningful decline (defined as a drop of 1 standard deviation or more on any BRIEF-2 subscale, confirmed on repeat testing 4 weeks later). This threshold is conservative. No cases of neurocognitive harm attributable to evolocumab have been published in any age group.

Injection-Site and Immunogenicity Monitoring

Children under 12 have less subcutaneous tissue than adults, particularly in the abdomen and thigh. The 420 mg dose (delivered via the SureClick autoinjector over approximately 60 seconds) requires adequate tissue depth.

In the HAUSER-RCT extension, injection-site reactions occurred in 3.2% of pediatric patients (ages 10 to 17), mostly erythema and mild pain [3]. For children under 10 using evolocumab off-label, injection-site assessment should occur at every visit:

• Visual inspection for nodules, induration, or persistent erythema lasting more than 72 hours
• Rotation documentation (right thigh, left thigh, abdomen, upper arm) using a body-map diary
• Pain assessment using the Wong-Baker FACES scale

Anti-drug antibodies (ADA): In FOURIER, 0.3% of patients developed binding antibodies; no neutralizing antibodies were detected [1]. If a child's LDL-C response attenuates by more than 25% from nadir without adherence issues, draw ADA titers. A positive neutralizing antibody result warrants switching to inclisiran (if age-appropriate) or returning to LDL apheresis.

Cardiovascular Imaging in Pediatric FH

Monitoring is not limited to blood tests. Children with HoFH develop aortic root and coronary ostial plaques in the first decade of life. The European Atherosclerosis Society consensus recommends:

• Echocardiography: at diagnosis, then annually to assess aortic root and valve calcification [9]
• Carotid intima-media thickness (cIMT): at diagnosis, then every 2 years; a validated surrogate in pediatric FH
• Coronary CT angiography: reserved for symptoms or cIMT above the 95th percentile; radiation concerns limit routine use in children

These imaging endpoints contextualize whether evolocumab is providing adequate atheroprotection or whether LDL apheresis should be added.

Adherence and Psychosocial Monitoring

Monthly injections in young children require family buy-in. Adherence rates in pediatric biologic therapies (drawn from rheumatology and dermatology data) range from 50% to 70% at 12 months. Monitoring adherence:

• Pharmacy refill records: request every 3 months
• LDL-C trajectory: an unexpected rise suggests missed doses
• Needle phobia screening: use the Children's Fear Scale at baseline and every 6 months; refer to pediatric psychology if score is 3 or higher

The financial toxicity of evolocumab (list price approximately $5,850/year) also warrants social work involvement. Prior authorization denials occur in over 30% of first submissions for pediatric patients, per a 2021 analysis published in JAMA Cardiology [10]. Document each monitoring visit thoroughly, as payers use gaps in monitoring as justification for coverage withdrawal.

When to Escalate or Discontinue

Clear stopping rules prevent harm and guide therapeutic pivots:

| Trigger | Action | |---------|--------| | ALT >5x ULN, confirmed | Hold evolocumab; recheck in 4 weeks | | Height velocity <10th percentile for 6 months | Endocrinology referral; consider dose reduction | | Neurocognitive decline (1 SD drop, confirmed) | Hold for 3 months; retest | | Neutralizing antibodies detected | Discontinue permanently | | LDL-C <15 mg/dL on two consecutive draws | Extend dosing interval to every 6 weeks | | Persistent injection-site nodules | Switch injection site or device; consider prefilled syringe over autoinjector |

Escalation to LDL apheresis should be discussed if LDL-C remains above 300 mg/dL despite maximum tolerated statin, ezetimibe, and evolocumab 420 mg monthly.

Practical Monitoring Calendar: Year One

A consolidated schedule for the treating clinician:

Week 0 (baseline): fasting lipid panel, hepatic panel, morning cortisol, 25-OH vitamin D, height/weight/Tanner, WISC-V or WPPSI, cIMT, echocardiogram, needle phobia screen, ADA baseline.

Week 4: fasting lipid panel, ALT/AST, injection-site check, adherence review.

Week 8: fasting lipid panel, injection-site check.

Week 12: fasting lipid panel, full hepatic panel, height/weight, BRIEF-2 parent form.

Week 16: fasting lipid panel (titration endpoint decision).

Week 24: fasting lipid panel, ALT/AST, height/weight/Tanner, BRIEF-2, injection-site assessment, morning cortisol (if LDL-C <40).

Week 36: fasting lipid panel, ALT/AST, height/weight.

Week 48: fasting lipid panel, full hepatic panel, height/weight/Tanner, full neuropsychological battery, echocardiogram, 25-OH vitamin D, cIMT, pharmacy refill audit.

This schedule generates 10 to 12 clinical encounters in the first year. The intensity is appropriate given the absence of long-term pediatric safety data for PCSK9 inhibition in children under 12.